UBS upgraded Jazz Pharmaceuticals to Buy and set a $307 price target, indicating a constructive setup not fully reflected in the market. The stock had already risen sharply, gaining 39% year to date and 116% over the past year, while the target remained above the $241.76 consensus. The upgrade centered on perceived fundamental inflection supported by strong recent results, including $1.07 billion in Q1 2026 revenue and adjusted EPS of $6.34. Product performance included Xywav sales of $408.2 million and Epidiolex sales of $249.8 million. The oncology portfolio grew 45%, and Zepzelca increased 60% to $101 million. A key upcoming catalyst is the August 25 PDUFA date for zanidatamab in first-line HER2-positive gastroesophageal cancer, with analysts projecting peak sales above $2 billion.
"UBS upgraded Jazz Pharmaceuticals ( NASDAQ:JAZZ | JAZZ Price Prediction) to Buy with a $307 price target, signaling the firm sees a constructive setup the market hasn't yet priced. For long-term investors, the call lands at a moment when fundamentals, pipeline catalysts, and valuation appear to be converging."
"Jazz Pharma stock has already run hard into the upgrade, climbing 39% year to date (YTD) and 116% over the past year. The UBS target sits well above the current consensus of $241.76, suggesting the firm sees room for further repricing."
"Jazz Pharmaceuticals delivered $1.07 billion in Q1 2026 revenue, a 19% year over year (YoY) gain, with adjusted EPS of $6.34 trouncing the $4.66 consensus. The oncology portfolio grew 45%, reinforcing the company's pivot narrative."
"The price target raise from UBS arrives ahead of a pivotal catalyst: the August 25 PDUFA date for zanidatamab in first-line HER2-positive gastroesophageal cancer. Analysts project peak sales potential of over $2 billion for the asset."
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]